In chemistry textbooks, green chemistry is a celebrated discipline. Solvent substitution, atom economy, the E-factor—the ideas have been around for over thirty years, and industry talks about them every year. Two researchers ran a full-industry health check, and the results delivered a heavy blow to that narrative.
Dobbelaere and Sneddon published this audit in *Angewandte Chemie International Edition* (DOI: 10.1002/anie.1677569), with Nature news covering it on September 25. They scanned 1.3 million chemical reactions in the USPTO patent database, using the Rxn-INSIGHT tool to tag solvent usage across more than 500 reaction types.
Here are the results: hazardous solvent usage was around 60% in 1976, and by 2016 it exceeded 70%. Forty years of the green chemistry movement, and the patent data's answer is: it's being used even more.
Substitution Is a Trap
Every time regulators target a hazardous solvent, industry swaps in a cheaper one that isn't yet under scrutiny. This pattern appears repeatedly in the audit: what gets phased out is a hazardous solvent, and what replaces it is also a hazardous solvent—total usage keeps climbing.
TFA Is Rising
Trifluoroacetic acid (TFA), a member of the PFAS family—so-called 'forever chemicals'—is bucking the trend in the data, driven by growth in peptide drug synthesis. The more peptide drug pipelines grow, the more TFA gets used, and the 'forever' in its nickname is the problem itself.
Nobody Is Watching Manufacturing
Two limitations of the audit deserve to be laid on the table. The USPTO database ends in 2016, so the last decade of change is invisible. Patents also mainly reflect solvent choices in early-stage drug discovery; actual volumes in scaled-up production were not measured. The 70% figure reflects laboratory-era habits—factories might do better, or worse, but nobody knows.
How Two Chemists Reacted
Lipshutz, a chemist who has long championed green solvents, offered only half a sentence: 'We have to stop.' The other interviewee, Leahy, described himself as 'disheartened.' Neither mentioned solutions—the sentiment itself is the verdict.
Why This Matters
The pharmaceutical industry is in a capacity-expansion cycle, with peptide drugs as the main track. Solvent processes locked in at the lab bench today will follow those molecules into factories over the next decade. The 1976–2016 curve is a cautionary tale: after forty years of slogans, without hard constraints from regulation and cost, solvent choices will not turn green on their own.
Many people in the chemical industry preach green transformation; few do the accounting. The ledger of 1.3 million reactions is open, and the numbers don't look good. Lipshutz's 'we have to stop' has been said for years, and the database stopped updating in 2016. When the next audit comes out, let's hope that curve turns downward.